lipegfilgrastim

Lipegfilgrastim is a long-acting, glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults receiving cytotoxic chemotherapy for malignancy (excluding chronic myeloid leukemia and myelodysplastic syndromes)[2][4][5]. It is administered as a subcutaneous injection. Lipegfilgrastim acts by binding to G-CSF receptors on hematopoietic progenitor cells, stimulating their proliferation and differentiation into mature neutrophils, which are then released from the bone marrow into peripheral blood[1][2][6]. The drug is a covalent conjugate of filgrastim with a single methoxy polyethylene glycol (PEG) molecule via a carbohydrate linker, which slows its clearance from the body and extends its half-life compared to non-pegylated forms[6][7]. Developed as an alternative to pegfilgrastim, lipegfilgrastim shows similar receptor binding but greater resistance to degradation by neutrophil elastase[2].

Brand names

Lonquex

Other names

lipegfilgrastimXM22XM-22XM 22